Table 1.

Patient sample characteristics

AML	BM Blasts (%)	CD117/CD34 (%)*	CG	FLT3	KIT
1	43	NA	t(3;21)(q26q22), CBF+	NA	NA
2	72	98.6	Diploid	0	NA
3	92	56.7	+8, t(3;17)(q21q25)	ITD	NA
4	86	53.5	t(9;21)(q31q22); del(4)(q12); add(21)(q22)	ITD	NA
5	92	0.3	t(9;11)(q22q23)	0	NA
6	81	77.3	t(3;3)(q21q26)	ITD	NA
7	58	89	t(4;12)(q12p13); der(13;15)(q10q10); del(20)(q11.2q13.3)	NA	NA
8	85	51	Diploid	ITD	0
9	94	57	+8, +10, +18, +22, +13	ITD	0
10	88	97.8	+8, inv(16)(p13.l1q22)	0	D816V
11	53	83.3	t(8;21)(q22q22)	0	D816V
12	65	95.2	t(8;21)(q22q22); del(7)(q34)	0	D816V

^*as measured by flow cytometry

BM, bone marrow; NA, not available; CG, cytogenetics; 0, no FLT3/KIT abnormalities detected; ITD, FLT3 internal tandem duplication; CBF, core binding factor